Protecting sight across Australia with autonomous AI detection for diabetic retinopathy, AMD, and glaucomatous optic nerve damage
Following a thorough regulatory review process, Eyenuk’s EyeArt system officially received Australian authorization on November 16, 2026, empowering clinicians to detect signs of diabetic retinopathy (including diabetic macular edema), age-related macular degeneration, and glaucomatous optic nerve damage in a single visit
Preventable vision loss places a growing burden on patients and healthcare systems across Australia. Age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma rank among the nation’s leading causes of blindness and low vision. AMD is the primary cause of vision loss in Australians over 50 (source), while DR remains the leading cause of preventable blindness among working-age adults (source). Early detection and timely intervention through routine retinal screening can prevent up to 98% of DR-related vision loss (source).
To help close critical screening gaps nationwide, Eyenuk began this journey in Australia in March 2026 and achieved official authorization on November 16, 2026. Listed on the Australian Register of Therapeutic Goods (ARTG), the EyeArt system is intended to detect signs of diabetic retinopathy (including diabetic macular edema), age-related macular degeneration (AMD), and glaucomatous optic nerve damage in patients at risk of vision loss using computerized analysis of images of the retina.
By evaluating a set of retinal images for three major sight-threatening conditions simultaneously, EyeArt dramatically expands the clinical value of point-of-care eye exams. Frontline providers across both metropolitan centers and underserved rural communities can capture retinal images using compatible fundus cameras and receive an autonomous diagnostic report in seconds. For those living with diabetes, this workflow directly supports Australian clinical guidelines by detecting diabetic retinopathy, while simultaneously flagging patients with signs of AMD or glaucomatous optic nerve damage so patients can be fast-tracked to specialists for follow-up care.
Bringing EyeArt’s multi-disease screening capabilities to Australia is a major step forward in advancing systemic health and preventing vision-threatening disease through retinal AI. By making fast, accurate retinal scans achievable during routine healthcare visits, we look forward to partnering with Australian healthcare networks and clinicians to protect sight across metro, regional, and remote communities alike.
About Eyenuk
Eyenuk is a global digital health technology company and leader in autonomous disease detection. Driven by our mission to prevent vision- and life-threatening disease and advance systemic health through retinal AI, our flagship EyeArt® system delivers rapid, autonomous retinal screenings at the point of care with regulatory clearances tailored by region. In Australia (TGA/ARTG), the European Union (CE MDR), Colombia, and Ecuador, it is authorized to detect signs of diabetic retinopathy (including diabetic macular edema), age-related macular degeneration (AMD), and glaucomatous optic nerve damage. In the United States (FDA 510(k)) and Canada (Health Canada), EyeArt is cleared for autonomous diabetic retinopathy (DR) detection. Backed by SOC 2 Type 2, GDPR, HIPAA, and MDSAP/ISO 13485:2016 certifications, Eyenuk partners with healthcare providers worldwide to protect sight and advance systemic health.